<DOC>
	<DOCNO>NCT00718484</DOCNO>
	<brief_summary>This randomize , control trial evaluate clinical benefit palifosfamide tris administer doxorubicin combination , compare single-agent doxorubicin administer subject diagnose unresectable metastatic soft-tissue sarcoma ( STS ) . Subjects meet entry criterion randomize 1 2 arm : either receive palifosfamide tris plus doxorubicin treatment single-agent doxorubicin . Subjects anthracyclin naïve .</brief_summary>
	<brief_title>A Study Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin Unresectable Metastatic Soft-tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Age ≥18 year 2 . Histological cytological documentation sarcoma ( exclude alveolar softpart sarcoma , chondrosarcoma , dermatofibrosarcoma , Ewing sarcoma , GIST , Kaposi sarcoma , mixed mesodermal tumor , osteosarcoma , radiation induce sarcoma , unresectable low grade liposarcoma ) fail ≤2 prior regimen include adjuvant therapy , ≤1 prior regimen metastatic/unresectable disease , treatment doxorubicin consider medically acceptable . Prior treatment IFOS acceptable . 3 . Have measurable disease per RECIST criterion ( Appendix 2 ) 4 . ECOG Performance Status 0 1 ( Appendix 3 ) 5 . Anthracyclin naïve 6 . Life expectancy ≥12 week 7 . Adequate bone marrow , liver , renal function , assess follow laboratory requirement conduct within 14 day prior dose : 1 . Hemoglobin ≥9.0 g/dL 2 . Absolute neutrophil count ( ANC ) ≥1,500/mm3 3 . Platelet count 100,000/mm3 4 . Total bilirubin ≤1.5×ULN ( upper limit normal ) 5 . ALT AST ≤2.5×ULN 5×ULN hepatic disease 6 . Partial thromboplastin [ PT ] INR/activated partial thromboplastin time [ PTT ] &lt; 1.5×ULN ( ≤2.0×ULN subject anticoagulation prophylactic regimen ) . Subjects therapeutically anticoagulated agent Coumadin ( warfarin sodium ) heparin allow provide prior evidence underlie abnormality coagulation parameter . If interaction study drug anticoagulant suspect , anticoagulation monitoring increase appropriate . 7 . Serum creatinine ≤ULN 8 . Written informed consent must obtain potential subject prior conduct studyspecific procedures 9 . Male female subject must agree use adequate birth control measures/barrier control course trial 10 . Women childbearing potential must urine pregnancy test perform within 14 day start treatment 1 . Has one follow sarcoma sub type : alveolar softpart sarcoma , chondrosarcoma , dermatofibrosarcoma , Ewing sarcoma , GIST , Kaposi sarcoma , mixed mesodermal tumor , osteosarcoma , radiation induce sarcoma , unresectable low grade liposarcoma . 2 . Clinically evident congestive heart failure &gt; Class II New York Heart Association ( NYHA ) guideline ( Appendix 4 ) 3 . Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia , ventricular arrhythmia classify Lown III , IV , V ( Appendix 4 ) 4 . History and/or sign active coronary artery disease/ischemia without angina pectoris 5 . Serious myocardial dysfunction define scintigraphically ( MUGA [ multiple gate acquisition scan ] , myocardial scintigram ) ultrasounddetermined absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % 6 . History HIV infection 7 . Prior nephrectomy history urinary tract obstruction 8 . Active , clinically serious infection require systemic antibacterial , antifungal , antiviral therapy 9 . Any major surgery within 3 week prior start treatment 10 . Metastatic brain meningeal tumor , unless subject &gt; 6 month definitive therapy negative imaging study within 4 week study entry . In addition , subject must undergo acute steroid therapy taper ( chronic steroid therapy acceptable , provide dose stable 1 month prior study start , follow screen radiographic study ) . 11 . Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis , &amp; T1 ] malignancy curatively treat &gt; 5 year prior entry ) 12 . Pregnancy lactation 13 . Substance abuse medical , psychological , social condition may interfere subject 's participation study evaluation study result 14 . Any condition unstable could jeopardize safety subject his/her compliance protocol requirement In addition , use follow therapy medications—prior concomitant—would exclude subject study : 15 . Anticancer chemotherapy , immunotherapy , investigational drug therapy study within 4 week study entry ( 6 week Mitomycin C ) 16 . Prior treatment doxorubicin 17 . Radiotherapy within 4 week study entry ( palliative radiation bone lesion permit start plan prior Cycle 1 , Day 1 ) 18 . Bone marrow transplant stem cell rescue within 4 month study entry 19 . Growth factor GCSF ( granulocyte colonystimulating factor/filgrastim ) , biological response modifier within 3 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>anthracyclin</keyword>
	<keyword>Palifosfamide</keyword>
	<keyword>IFOS</keyword>
</DOC>